Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 53 Ovarian Neoplasms 4 Prostatic Neoplasms 3 Neoplasms 3 Inflammatory Breast Neoplasms 3 HER2-positive Breast Cancer 3 Carcinoma, Non-Small-Cell Lung 3 Stomach Neoplasms 2 Solid Tumor 2 Rectal Neoplasms 2 Neoplasm Metastasis 2 Colonic Neoplasms 2 Urinary Bladder Neoplasms 1 Solid Cancers 1 Patient Preference 1 Pancreatic Neoplasms 1 Neuroendocrine Tumors 1 Neuroblastoma 1 Neoplasms, Unknown Primary 1 Multiple Endocrine Neoplasia 1 Malignant Solid Neoplasm 1 Lung Neoplasms 1 Locally Advanced Breast Cancer 1 Her2-Positive Breast Cancer 1 HER2-positive Metastatic Breast Cancer 1 HER2-positive Early Breast Cancer 1 HER2-Positive Early Breast Cancer 1 HER2 Positive Breast Cancer 1 Fallopian Tube Neoplasms 1 Colorectal Neoplasms 1

Interventions

Bevacizumab 112 Fluorouracil 98 Oxaliplatin 96 Leucovorin 96 Irinotecan 86 Capecitabine 73 Cetuximab 64 Panitumumab 42 pembrolizumab 38 regorafenib 28 Nivolumab 23 IFL protocol 22 Folfox protocol 21 trifluridine tipiracil drug combination 14 Radiotherapy 13 durvalumab 11 Gemcitabine 10 Celecoxib 10 tremelimumab 7 binimetinib 7 aflibercept 7 Drug Therapy 7 Disulfides 7 Cyclophosphamide 7 Trifluridine 6 Trastuzumab 6 Sunitinib 6 Paclitaxel 6 Immunoglobulin G 6 Colonoscopy 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Colorectal Neoplasms × pertuzumab × Clear all

NCT02291289 2024-05-06

MODUL

Hoffmann-La Roche

Phase 2 Completed

1,044 enrolled 21 charts

Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡